Potential market opportunity for Rubius' red cell platform - analysts

Rubius Therapeutics

13/08/2018 11:05

** At least 2 brokerages initiate coverage on Rubius
Therapeutics  RUBY.O , citing Rubius' red cell platform has
potential market opportunity in cell therapy
    ** Morgan Stanley starts with "overweight" rating; says
Rubius' red cell platform has broad reach, significant IP
barriers and a potential market opportunity 5-20x that of other
cell therapy platforms
    ** MS sees initial rare disease data in 2019 as derisking
that platform vertical and a significant driver of RUBY
    ** Says unlike other cell therapy platforms, red blood cells
can access a broad range of diseases from enzyme replacement to
cancer to autoimmune
    ** Jefferies starts coverage on stock with "buy" rating;
says its a "rare" platform technology that could broadly address
a number of blockbuster markets
    ** Says Rubius' red cell platform technology offers key
proof of concept data in 2019 (key catalyst) and across rare
diseases, oncology, and immunology, offering investors
significant 100-200 percent upside potential over next 1-2 years
    ** Jefferies, which acted as joint-bookrunner in the IPO of
Rubius, says in long-term, RUBY has unique potential to be a
"big idea" in biotech
    ** MS has set a $37 PT on the Rubius stock, while Jefferies
has a $40 PT; Rubius' shares closed Friday at $23.76 on the
Nasdaq

 (Reporting by: Aniruddha Chakrabarty)
 ((aniruddha.c.thomsonreuters.com@reuters.net))